Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Medical - Care Facilities

Healthcare
$20.95 -0.76%

-$0.18 today

Market cap
$11.26B
Beta
0.81
P/E (TTM)
11.9
EPS (TTM)
$3.43
Dividend yield
3.65%
52W Low $20.02High $28.87

Volume 1.92M

Average 0.72M

FMS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Fresenius Medical Care AG & Co. KGaANYSE: FMS

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation outflow grows to €0

Q2 FY2026 stock-based compensation was €0, compared with €0 a year earlier. Trailing-twelve-month stock-based compensation was €0.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near €0 or moves back toward the trailing-twelve-month quarterly average of €0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€0— QoQ
Last fiscal yearDec 2025
€0— YoY
LTMJun 2026
€0-100.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
—

Stock-Based Compensation vs competitors

How FMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 4, against a peer median of +67.9%.
  • Stock-based compensation amounts to 0.0% of revenue for FMS, versus a peer median of 5.5%.
FMS Competitors
Stock-Based Compensation for FMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DVADaVita Inc.LTM Jun 2026$131.58M USD+12.9%+13.6%0.9%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$72.84M USD+70.9%+5.6%11.2%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$12.76M USD+67.9%-14.2%5.5%
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€0 EUR-100.0%—0.0%
Peer median (excluding FMS) —+67.9%+5.6%5.5%

Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.22B894.33M732.46M740.87M939.75M
Depreciation & Amortization1.62B1.84B1.75B1.74B1.5B
Deferred Income Tax67.26M(41.47M)(122.15M)(72.67M)(26.14M)
Stock-Based Compensation0032.52M00
Change in Working Capital(97.77M)(128.07M)561.28M444.31M132.78M
Accounts Receivables(163.2M)(46.68M)(151.84M)(73.48M)(66.34M)
Inventory(48.53M)(204.31M)(13.14M)107.9M(238.84M)
Accounts Payables(363.96M)(356.79M)108.48M155.59M(14.18M)
Other Working Capital477.91M479.71M617.78M254.3M452.14M
Other Non-Cash Items(322.7M)(395.77M)(327.27M)(468.62M)28.38M
Operating Cash Flow2.49B2.17B2.63B2.39B2.58B
Capital Expenditures(854.36M)(723.99M)(684.6M)(699.36M)(879.24M)
Acquisitions (Net)(381.73M)1.03M137M606.68M223.34M
Purchases of Investments(129.08M)(105.64M)(102.36M)(81.5M)(85.99M)
Sales of Investments144.52M57.67M89.6M75.13M80.2M
Other Investing Activities24.42M36.21M16.14M14.1M0
Investing Cash Flow(1.2B)(734.73M)(544.23M)(84.94M)(666.18M)
Debt Repayment(358.9M)(1.12B)(1.19B)(1.91B)767.1M
Common Stock Issued00000
Common Stock Repurchased0000(562.19M)
Dividends Paid(392.46M)(395.56M)(328.62M)(349.16M)(405.84M)
Other Financing Activities(273.02M)(103.8M)(340.11M)(314.99M)(1.17B)
Financing Cash Flow(1.02B)(1.62B)(1.86B)(2.57B)(1.38B)
Effect of Forex Changes131.23M(23.16M)(72.61M)26.2M24.97M
Net Change in Cash400.12M(207.87M)153.44M(241.9M)558.32M
Free Cash Flow1.64B1.44B1.94B1.69B1.7B

Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.